A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer. READ MORE
October 15-18 marked the annual International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC). Oncologists from over 100 countries came together in Japan to discuss the latest developments and findings related to thoracic malignancy research.
A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer.
A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer.
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
Elderly lung cancer patients who are black or from less educated communities are less likely to get the combination of chemotherapy and radiation that’s linked to better survival odds.
Experts in lung cancer are set to reveal key recommendations and updates to screening evidence at the CHEST Annual Meeting.